## SEC Form 5

## FORM 5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Form 3 Holdings Reported.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

ANNULAL STATEMENT OF CHANGES IN RENEEICIAL

3235-0362 OMB Number:

Estimated average burden hours per response: 1.0

Form 4 Transaction	ons Reported.		or Section 30(h) of the Investment Company Act of 1940							
1. Name and Addres	1 0	n*	2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>TherapeuticsMD, Inc.</u> [ TXMD ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
Finizio Rober	<u>[G</u>		<u></u>	X Director X 10% Owner			10% Owner			
(Last) 6800 BROKEN S	(First) (Middle)		3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year) 12/31/2013		Officer (give title below)		Other (specify below)			
3RD FLOOR		, ,								
(Street)			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)						
BOCA RATON,	FL	33487		X	Form filed by One F	Reporti	ng Person			
					Form filed by More than One Reporting Person					
(City)	(State)	(Zip)			1 013011					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned at end of	6. Ownership Form: Direct (D) or	7. Nature of Indirect Beneficial Ownership	
		(Monuinday) real)	6)	Amount	(A) or (D)	Price	Issuer's Fiscal Year (Instr. 3 and 4)	Indirect (I) (Instr. 4)	(Instr. 4)	
Common Stock	12/10/2013		G	50,000	D	\$0	22,111,586	D		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Nur of Derive Secur Acqui (A) or Dispo of (D) (Instr. and 5	ative rities ired osed . 3, 4	6. Date Exerc Expiration Da (Month/Day/Y	ate	7. Title Amoun Securit Underly Derivat Securit and 4)	it of ies ying	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

## /s/ Robert G. Finizio

\*\* Signature of Reporting Person Date

01/23/2014

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

OMB APPROVAL

ANNOAL	OWNERSHIP	CIAL		
Filed	pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940			
(Middle) Y NW,	2. Issuer Name and Ticker or Trading Symbol <u>TherapeuticsMD, Inc.</u> [ TXMD ] 3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year) 12/31/2013		5. Relationshi (Check all app X Direc X Offic below	
33487	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indivi Line) X	dual o Form	